Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
De novo Ph-positive MDS with the micro BCR::ABL1 (e19a2/p230) transcript is rare. Here, we report a case of MDS with multilineage dysplasia in an 86-year-old woman. Reverse transcription polymerase chain reaction (RT-PCR) showed the following karyotype: 46, XX, t(9;22)(q34.1;q11.2), i(17)(q10) [20], and p230 BCR::ABL1. Targeted NGS at diagnosis revealed mutations in CSF3R, BCOR, SRSF2, and ASXL1. Low-dose dasatinib (20 mg/day) reduced BCR::ABL1 levels (FISH negative, RT-PCR positive), but had no effect on anemia, dysplasia, or transfusion frequency. At six months, panel results showed loss of all mutations except ASXL1, as well as clearance of Ph-positive subclones. However, an ASXL1 founder clone persisted. Post-treatment chromosome analysis was not feasible because of poor cell growth. Serial genomics suggested that Ph positivity was a late/secondary event on a pre-existing ASXL1-mutant background. In Ph-positive de novo MDS, BCR::ABL1 transcript responses alone may not reflect disease control when an adverse founder clone persists. Integrating panel-based NGS with fusion transcript monitoring may improve therapeutic decision-making and prognostic assessment.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Ph-positive de novo myelodysplastic syndrome has rarely reported [1, 2], and its clinicopathologic features and management remain insufficiently defined. Among BCR::ABL1 variants, micro BCR::ABL1 (μ-bcr) is the fusion of BCR exon 19 and ABL1 exon 2 (e19a2), which results in a 230-kDa protein, and can be a molecular diagnostic marker for neutrophilic-chronic myeloid leukemia (CML-N) [3]. The significance of u-bcr in Ph-positive de novo MDS is poorly characterized owing to the paucity of reports.
Two literature reviews (Ma J et al. and Qi S et al.) identified 24 unique cases after accounting for seven overlapping reports, and only one involved the μ-bcr [4, 5]. Against this background, we herein report a case of Ph-positive de novo MDS with μ-bcr and isochromosome 17q [i(17q)], documenting serial genomic changes during low-dose dasatinib.
Anzeige
Materials and methods
Total RNA was extracted from bone marrow cells, and complementary DNA (cDNA) was synthesized in vitro for RT-PCR to detect BCR::ABL1 transcripts, including μ-bcr e19a2 (p230). NGS analysis was performed using the Tru Sight Myeloid Sequencing Panel (Illumina). Genomic DNA was extracted from bone-marrow cells at diagnosis and after 6 months of dasatinib for targeted NGS using a myeloid panel per validated laboratory procedures. The analytical limit of detection for single-nucleotide variants on this panel was approximately 2–5% variant allele frequency, depending on coverage.
Quality filtering for the generated read data was performed using fastp (ver. 0.23.2) with default parameters. The filtered sequence data were aligned to the RefSeq Human Genome GRCh37 using Burrows-Wheeler Aligner (ver. 0.7.12). The mapping data were processed using Samtools (ver. 1.12), Picard (ver. 2.23.0), and GATK (ver. 4.1.9.0). Calling of single-nucleotide variants (SNVs) was performed using Mutect2, HaplotypeCaller, VarScan2 (ver. 2.3), LoFreq (ver. 2.1.3.1), and FreeBayes (ver. 1.3.6,arXiv:1207.3907). The identified variants were aligned using the bcftools (ver. 1.18) and annotated using ANNOVAR.
Case presentation
An 86-year-old woman presented with anemia. She had chronic heart failure (CHF) and chronic kidney disease (CKD). Laboratory tests revealed the following findings: hemoglobin, 6.5 g/dL; platelet count, 158 × 109/L; leukocyte count, 5.0 × 109/L without blasts; prothrombin time (PT), 27.1 s; activated partial thromboplastin time (APTT), 50.9 s; FDP, 2.9 µg/mL; D-dimer, 0.80 µg/mL; fibrinogen 291.0 mg/dL. A bone marrow examination revealed a nucleated cell count of 426 × 109/L, myeloblasts with 2.3% positive for peroxidase (Fig. 1A-a), and multilineage dysplasia was recognized including neutrophilic degranulation, pseudo-Pelger nuclear anomaly, erythroblast of megaloblastic change and single nucleus megakaryocyte (Fig. 1A-b–e). Flow cytometry revealed positivity for several myeloid markers including CD 13, CD 33, CD 34, CD 117, HLA-DR and MPO (Fig. 1B). A chromosomal analysis revealed 46, XX, t(9;22)(q34.1;q11.2), i(17)(q10) [20] (Fig. 1C). A FISH analysis of bcr::abl1 revealed 87% positivity in the bone marrow (Fig. 1D) and peripheral neutrophils (Fig. 1E). Reverse transcription polymerase chain reaction (RT-PCR) results were positive for μ-bcr and negative for M-bcr (Fig. 1F). RT-PCR analysis revealed that μ-bcr mainly produced Ph-positive MDS in this case. The patient was finally diagnosed with myelodysplastic syndrome with multilineage dysplasia (MDS-MLD) with μ-bcr. The revised International Prognostic Scoring System (IPSS-R) score was high (4.5).
Fig. 1
Bone marrow sample and detection of the BCR::ABL1 fusion gene at the diagnosis. A Blasts and multilineage dysplasia of the bone marrow sample obtained at the diagnosis. B Flow cytometry by CD45 gating. C Chromosomal analysis. D FISH analysis of bcr::abl1 in bone marrow. E FISH analysis of neutrophil-bcr::abl1 in peripheral blood. F RT-PCR of major bcr::abl1 (left lane) and micro bcr::abl1 (right lane). Actin beta (ACTB) was used as the control. The band of the major bcr::abl1 should be shown in 371 bp, but an abnormal band is exhibited in the position of the asterisk mark (*)
The use of dasatinib for MDS has not been approved by the insurance. After the use of dasatinib was approved by the ethics committee, informed consent for dasatinib treatment was obtained. The patient was treated with dasatinib (20 mg/day) and darbepoetin alfa according to age and CKD. After 6 months, a bone marrow examination revealed a nucleated cell count of 99 × 109/L, myeloblasts with 2.3%, and multilineage dysplasia. Chromosomal analysis was not evaluated by poor cell growth. Therefore, it is unclear whether i(17)(q10) remained. FISH analysis of bcr::abl1 did not detect split signals, but RT-PCR was positive for μ-bcr (Fig. 2). Dasatinib and darbepoetin alfa were concurrently administered, but the frequency of blood transfusion did not change, and bone marrow dysplasia persisted. No adverse effects, including pleural effusion, were observed, and the patient was able to continue treatment with dasatinib 20 mg.
Fig. 2
FISH analysis and RT-PCR after dasatinib treatment. A FISH analysis of bcr::abl1 in bone marrow. B RT-PCR of micro bcr::abl1
NGS revealed mutations in CSF3R, BCOR, SRSF2, and ASXL1 at the time of diagnosis; the frequency of each variant allele is shown in Table 1. During the course of treatment, all mutations except for ASXL1 became undetectable by 6 months. However, 8 months after diagnosis, the patient’s performance status declined due to congestive heart failure and chronic kidney disease, and she became unable to continue outpatient visits. Given that the ASXL1 mutation–associated with treatment resistance and poor prognosis–persisted despite dasatinib therapy, and her general condition had deteriorated, and the treatment was discontinued.
Table 1
NGS analysis at the diagnosis and after dasatinib treatment
Gene
At a diagnosis (VAF)
After dasatinib treatment (VAF)
BCOR c.C4870T: p.Q1624X
0.29
0
CSF3R c.690delC: p.P230fs
0.1
0
CSF3R c.1404delC: p.P468fs
0.071
0
SRSF2 c.287delC: p.P96fs
0.06
0
ASXL1 c.1927delG: p.G643fs
0.08
0.1
NGS next generation sequencing, VAF variant allele frequency
Discussion
Cases of Ph-positive de novo MDS are rare. Ma J et al. and Qi S et al. summarized 24 cases of Ph-positive de novo MDS in a case report with two literature reviews; however, only one case of μ-bcr could not continue imatinib treatment [4, 5]. We report a case of Ph-positive de novo MDS with μ-bcr in which the patient continued to take dasatinib for 8 months.
After 6 months of low-dose dasatinib, the BCR::ABL1 clone diminished, while ASXL1 persisted and marrow dysplasia and transfusion need were unchanged. This pattern supports ASXL1 as a founder clone and suggests that the Ph chromosome was a secondary event in disease evolution, contrasting with its initiating role in CML or Ph-positive ALL.
Persistence of an adverse-risk founder such as ASXL1 may predict limited benefit of tyrosine kinase inhibitors (TKIs) monotherapy despite transcript responses. Management in such settings may consider dose escalation when feasible, hypomethylating agent-based therapy, or allogeneic transplantation in eligible patients, alongside serial NGS to align treatment with clonal dynamics [6‐8].
In this case, i(17q) is a single chromosomal abnormality. Isolated isochromosome 17q, i(17q), accounts for less than 1% of myeloid neoplasms, including AML, MDS, and myeloproliferative neoplasms (MPN), and frequently harbors mutations in SETBP1, ASXL1, SRSF2, and NRAS [9, 10]. The present case of i(17q) featured typical mutations in SRSF2 and ASXL1.
Reported outcomes are heterogeneous: Additional chromosomal abnormalities were frequently found. Out of 24 patients, 9 (36%) cases were Ph-positive without additional chromosomal abnormalities, 9 (36%) cases were Ph-positive with a complex karyotype, and 6 (24%) cases were Ph-positive with single additional chromosomal abnormalities. TKIs sensitivity is sometimes seen when Ph occurs alone or with a single additional lesion, whereas durability is short when complex karyotypes or multiple adverse mutations coexist. Consolidating these observations emphasizes the contrast and may aid clinical decision-making.
Low-dose dasatinib (20 mg/day) reduced μ-bcr levels. If dasatinib was increased to a regular dose and used for a long time, it might have been useful for reducing μ-bcr. It was assumed that the residual ASXL1 mutation after dasatinib treatment was a founder clone, and that mutations including CSF3R, BCOR and SRSF2 were subclones after the acquisition of μ-bcr. Owing to the residual ASXL1 mutation, dasatinib treatment did not improve anemia. Therefore, dasatinib monotherapy has a limited effect.
In conclusion, we reported a case of Ph-positive de novo MDS with μ-bcr. Mutations in CSF3R, BCOR, SRSF2, ASXL1, and isolated isochromosome 17q may contribute to the progression of MDS. Before and after treatment with TKIs, the detection of residual founder clones using NGS is useful for deciding the therapeutic strategies and predicting the prognosis. Further analyses with the accumulation of additional cases are necessary to improve the prognosis.
Anzeige
Acknowledgments
We thank Mr. Akinori Takase and Mr. Masayuki Tanaka (Medical Science College Office, Tokai University) for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (H.K.).
Declarations
Conflict of interest
The authors declare no conflicts of interest in association with the present study.
Informed consent
Patient samples of peripheral blood cells and bone marrow were obtained after receiving written informed consent. The samples were obtained in accordance with the Declaration of Helsinki and were approved by the Tokai University Committee on Clinical Investigation (permit number: #15I-26).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Unsere Produktempfehlungen
e.Med Interdisziplinär
Kombi-Abonnement
Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag
Mit e.MedInterdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, Louwagie A, et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica. 1996;81:423–7.PubMed
2.
Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res. 2004;28(6):579–86.CrossRefPubMed
3.
Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88(7):2410–4.CrossRefPubMed
4.
Ma J, Guan J, Chen B. De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230 BCR::ABL fusion transcript: a case report with a literature review. Hematology. 2023;28(1):2220220.CrossRefPubMed
5.
Qi S, Wang F, Liu Y, Zhao J, Wang Y, Huang S. TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: a case report and literature review. Medicine (Baltimore). 2022;101(46):e31874.CrossRefPubMed
6.
Yang L, Wei X, Gong Y. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Cancer Med. 2024;13(1):e6871.CrossRefPubMed
7.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506.CrossRefPubMedPubMedCentral
8.
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27.CrossRefPubMedPubMedCentral
9.
Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45:942–6.CrossRefPubMedPubMedCentral
10.
Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, et al. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016;7(12):14251–8.CrossRefPubMedPubMedCentral
Auch wer in subjektiv guter Verfassung 80 Jahre oder älter wird, verstirbt letztlich an ähnlichen Ursachen wie weniger Fitte. Dafür sprechen zumindest Daten aus dem US-amerikanischen National Health Interview Survey.
Serielle hs-TnT-Auswertungen könnten bei Personen, die mit Immuncheckpointhemmern behandelt werden, dabei helfen, kardiovaskuläre Therapierisiken besser einzuschätzen. Dafür sprechen zumindest retrospektive Daten aus den USA.
Entwickeln Patienten nach einer Koloskopie mit Polypenentfernung einen bösartigen kolorektalen Tumor, handelt es sich am häufigsten um einen Intervallkrebs noch vor der nächsten Kontrollkoloskopie. Das haben US-Forscher herausgefunden und auch die Gründe untersucht.
Eine Ärztin des Klinikums Bremen-Mitte soll in 34 Fällen Befunde von Gewebeproben fehlerhaft interpretiert haben. Viele Patientinnen erhielten deshalb eine unnötige Antikörper- oder Chemotherapie.
